Back to Search Start Over

International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry

Authors :
Filippatos, Gerasimos
Sana Khan, Sadiya
Ambrosy, Andrew P.
Cleland, John G. F.
Collins, Sean P.
Lam, Carolyn S. P.
Angermann, Christiane E.
Ertl, Georg
Dahlström, Ulf
Hu, Dayi
Dickstein, Kenneth
Perrone, Sergio V.
Ghadanfar, Mathieu
Bermann, Georgina
Noe, Adele
Schweizer, Anja
Maier, Thomas
Gheorghiade, Mihai
Filippatos, Gerasimos
Sana Khan, Sadiya
Ambrosy, Andrew P.
Cleland, John G. F.
Collins, Sean P.
Lam, Carolyn S. P.
Angermann, Christiane E.
Ertl, Georg
Dahlström, Ulf
Hu, Dayi
Dickstein, Kenneth
Perrone, Sergio V.
Ghadanfar, Mathieu
Bermann, Georgina
Noe, Adele
Schweizer, Anja
Maier, Thomas
Gheorghiade, Mihai
Publication Year :
2015

Abstract

AimsThe clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF (International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure) is a global, prospective, and observational study designed to characterize patient trajectories longitudinally during and following an index hospitalization for HF. MethodsData collection for the registry will be conducted at approximate to 300 sites located in approximate to 40 countries. Comprehensive data including demographics, clinical presentation, co-morbidities, treatment patterns, quality of life, in-hospital and post-discharge outcomes, and health utilization and costs will be collected. Enrolment of approximate to 20 000 adult patients hospitalized with new-onset (first diagnosis) HF or decompensation of chronic HF over a 3-year period is planned with subsequent 3 years follow-up. PerspectiveThe REPORT-HF registry will explore the clinical characteristics, management, and outcomes of HF worldwide. This global research programme may have implications for the formulation of public health policy and the design and conduct of international clinical trials.<br />Funding Agencies|Novartis Pharma AG

Details

Database :
OAIster
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1233619585
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1002.ejhf.262